⑷　入札の無効　本公告に示した競争参加資格のない者の提出した入札書、入札者に求められる義務を履行しなかった者の提出した入札書、その他入札説明書による。
⑸　契約書作成の要否　要。
⑹　落札者の決定方法　本公告に示した物品を納入できると学長が判断した入札者であって、旭川医科大学契約細則第13条の規定に基づいて作成された予定価格の制限の範囲内で最低価格をもって有効な入札を行った入札者を落札者とする。
⑺　手続における交渉の有無　無。
⑻　その他　詳細は、入札説明書による。

5　Summary
⑴　Official in charge of disbursement of the procuring entity : Akitoshi Yoshida, President, Asahikawa Medical University
⑵　Classification of the products to be procured : 4
⑶　Nature and quantity of the products to be purchased :
A　Cetuximab (Genetical Recombination) (100 mg／1 vial) 1,158 vials
B　Aflibercept (Genetical Recombination) (40 mg／ml／1 vial) 760 vials
C　Tocilizumab (Genetical Recombination) (400 mg／1 vial) 229 vials
D　Brentuximab Vedotin (Genetical Recombination) (50 mg／1 vial) 40 vials
E　Bevacizumab (Genetical Recombination) (100 mg／4 ml／1 vial) 1,158 vials
F　Bevacizumab (Genetical Recombination) (400 mg／16 ml／1 vial) 673 vials
G　Paclitaxel (100 mg／1 vial) 842 vials
H　Pemetrexed Sodium Hydrate (100 mg／1 vial) 442 vials
I　Pemetrexed Sodium Hydrate (500 mg／1 vial) 155 vials
J　Palonosetron Hydrochloride (0.75 mg／5 vials／1 case) 466 cases
K　Infliximab (Genetical Recombination), Infliximab BS for I.V. Infusion 100mg「NK」 or its equivalent or its equivalent (100 mg／1 vial) 872 vials
L　Abatacept (Genetical Recombination) (250 mg／1 vial) 320 vials
M　Trastuzumab Emtansine (Genetical Recombination) (100 mg／1 vial) 238 vials
N　Pembrolizumab (Genetical Recombination) (100 mg／4 ml／1 vial) 570 vials
O　Ramucirumab (Genetical Recombination) (100 mg／10ml／1 vial) 256 vials
P　Ramucirumab (Genetical Recombination) (500 mg／50 ml／1 vial) 88 vials
Q　Pegfilgrastim (Genetical Recombination) (3.6 mg／1 vial) 319 vials
R　Palivizumab (Genetical Recombination) (100 mg／1 vial) 340 vials
S　Golimumab (Genetical Recombination) (50 mg／0.5 ml／1 vial) 343 vials
T　Ustekinumab (Genetical Recombination) (45 mg／1 vial) 232 vials
U　Nusinersen Sodium (12 mg／5 ml／1 vial) 6 vials
V　Goserelin Acetate (10.8 mg／1 syringe) 584 syringes
W　Eculizumab (Genetical Recombination) (300 mg／1 vial) 161 vials
X　Human fibrinogen Human thrombin (9.5 cm × 4.8 cm／1 sheet) 419 sheets
Y　Daratumumab (Genetical Recombination) (400 mg／20 ml／1 vial) 156 vials
Z　Atezolizumab (Genetical Recombination) (1200 mg／20 ml／1 vial) 52 vials
AA　Ixekizumab (Genetical Recombination) (80 mg／1 ml／1 kit) 163 kits
AB　Mepolizumab (Genetical Recombination) (100 mg／1 vial) 112 vials
AC　Somatropin (Genetical Recombination) (10 mg／1 vial) 458 vials
AD　Pertuzumab (Genetical Recombination) (420 mg／14 ml／1 vial) 178 vials
AE　Trastuzumab (Genetical Recombination) (150 mg／1 vial) 1,206 vials
AF　Trastuzumab (Genetical Recombination) (60 mg／1 vial) 1,608 vials
AG　Eribulin Mesilate (1 mg／1 vial) 608 vials
AH　Azacitidine (100 mg／1 vial) 470 vials
AI　Agalsidase Beta (Genetical Recombination) (35 mg／1 vial) 26 vials
AJ　Agalsidase Beta (Genetical Recombination) (5 mg／1 vial)　382 vials
AK　Micafungin Sodium (50　mg　／　10 vials／1 case) 446 cases
AL　fulvestrant (250 mg／2 vials／1 case) 376 cases
AM　Sugammadex Sodium (200 mg／10 vials／1 case) 442 cases
AN　Bortezomib (3 mg／1 vial) 450 vials
AO　Botulinum Toxin Type A (100 units／1 vial) 290 vials
AP　Pomalidomide (4 mg／7 capsules／1 case) 114 cases
AQ　Alglucosidase Alfa (Genetical Recombination) (50 mg／1 vial) 672 vials
AR　Ipilimumab (Genetical Recombination) (50 mg／10 ml／1 vial) 56 vials
AS　Denosumab　(Genetical Recombination) (120 mg／1 vial) 876 vials
AT　Thrombomodulin Alfa (Genetical Recombination) (12800 units／10 vials／1 case) 62 cases
AU　Rituximab (Genetical Recombination) (500 mg／ml／1 vial) 244 vials
AV　Agalsidase Alfa (Genetical Recombination) (3.5 mg／1 vial) 180 vials
AW　Leuprorelin Acetate (22.5 mg／1 syringe) 200 syringes
AX　Ranibizumab (Genetical Recombination) (10 mg／ml／1 syringe) 424 syringes
AY　Lenalidomide Hydrate (5 mg／40 capsules／1 case) 160 cases
AZ　Infliximab (Genetical Recombination), Remicade for I.V. Infusion 100 or its equivalent or its equivalent (100 mg／1 vial) 3,490 vials
⑷　Delivery period : From 1 April, 2019 through 31 March, 2020
⑸　Delivery place : Asahikawa Medical University Hospital
⑹　Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A　not come under Article 4 and 5 of the Regulation concerning the Contract for Asahikawa Medical University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B　have the Grade A, Grade B or Grade C qualification during fiscal 2019 in the Hokkaido area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C　prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D　not be currently under a suspension of business order as instructed by President, Asahikawa Medical University.
⑺　Time limit of tender : 17 : 00　8 March, 2019
⑻　Contact point for the notice : Kouta Kitachi, Procurement Section, Accounting Division, Asahikawa Medical University, 2―1―1―1 Midorigaokahigashi, Asahikawa-shi, Hokkaido, 078―8510 Japan, TEL 0166―69―3071

○第16号

1　調達内容
⑴　品目分類番号　4
⑵　購入等件名及び数量
A　エドワーズライフサイエンス　サピエン３コマンダー経大腿アプローチキット（9600CM23J　サイズ23㎜）又はこれと同等のもの　22組
B　エドワーズライフサイエンス　サピエン３コマンダー経大腿アプローチキット（9600CM26J　サイズ26㎜）又はこれと同等のもの　12組

第明治三十二種郵便物認可　平成三十一年三月三十一日